HALO News and Press, Halozyme Therapeutics Inc. From 10/19/23

2023-10-19 07:49:48 ET More on Bristol-Myers, Halozyme, etc. Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? Bristol Myers' Opdivo gets...

Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma PR Newswire BMS in discussions with health auth...

2023-10-18 12:46:20 ET More on Genmab Genmab Is Down To Attractive Levels Genmab A/S (GMAB) Q2 2023 Earnings Call Transcript Seagen, Genmab succeed in Phase 3 trial for cervical cancer therapy Genmab raises FY 2023 guidance on back of Darzalex sales S...

Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference PR Newswire Study met primary end point and d...

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery PR Newswire Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHAN...

2023-09-12 17:59:16 ET Summary Halozyme Therapeutics, based in San Diego, has developed ENHANZE technology based around its proprietary enzyme, rHuPH20. The enzyme makes it possible for many intravenously administered drugs to be administered subcutaneously instead. Not only i...

2023-08-29 07:14:31 ET More on Halozyme, Roche, etc. Halozyme Therapeutics, Inc. ( HALO ) Q2 2023 Earnings Call Transcript Roche: FX Drug But Positive Outlook Roche Holding AG ( OTCQX:RHHBY ) Q2 2023 Earnings Call Transcript Halozyme: Inflection Point...

Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain PR Newswire First subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain Tecentriq ® subcutaneous formulation with E...

2023-08-08 21:44:07 ET Halozyme Therapeutics, Inc. (HALO) Q2 2023 Earnings Conference Call August 8, 2023, 04:30 AM ET Company Participants Tram Bui - VP, IR and Corporate Communications Helen Torley - President and CEO Nicole LaBrosse - CFO Conference Call...

2023-08-08 16:04:28 ET Halozyme Therapeutics press release ( NASDAQ: HALO ): Q2 Non-GAAP EPS of $0.74 beats by $0.10 . Revenue of $221.04M (+45.1% Y/Y) beats by $21.09M . Royalty Revenue Increased 31% YOY to Record $111.7 million 2023 Outlook: Total rev...